Company Information
- Type:
- Company
- Country:
- Japan
- Sector:
- Pharmaceuticals & Biotechnology
- Ownership:
- Publicly Listed
- Global Compact Status:
- Active
- Participant Since
- 28 October 2011 Letter of Commitment
- Next Communication on Progress (COP) due on:
- 31 July 2025
Financial Information
Forward Faster
Affiliated Subsidiaries
Country | Company Name |
---|---|
Denmark | Astellas Pharma a/s |
Communication On Progress
Published On | Title | Level/Status |
---|---|---|
25-Jul-2024 | 2024 Communication on Progress | Submitted |
28-Feb-2024 | 2023 Communication on Progress | Submitted |
29-Nov-2022 | Communication on Progress, 2022 | Active |
29-Nov-2022 | Communication on Progress 2022 | Active |
01-Dec-2021 | Annual Report 2021 for Communication on Progress | Active |
09-Dec-2020 | Annual Report 2020 for Communication on Progress | Active |
08-Jan-2020 | Annual Report 2019 for Communication on Progress | Active |
18-Sep-2019 | Grace Letter | Not applicable |
12-Oct-2018 | Communication on Progress | Active |
13-Oct-2017 | Annual Report 2017 for Communication on Progress Details | Active |
14-Oct-2016 | Annual Report 2016 for Communication on Progress | Active |
15-Oct-2015 | Communication on Progress | Active |
15-Oct-2014 | Astellas Annual Report 2014 | Active |
18-Oct-2013 | Communication on Progress | Active |
18-Oct-2012 | Astellas Annual Report 2012 | Active |
Note: Responsibility for the content of participants' public communication related to the Ten Principles of the UN Global Compact and their implementation lies with participants themselves and not with the UN Global Compact.
Note on levels: Not applicable refers to the period when the Communication on Progress (CoP) did not require differentiation levels. With the new CoP, for the 2022 Early Adopter Programme, and for 2023, there will be no differentiation levels.